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Abstract 29 
Aims: To assess the prevalence of potentially inappropriate medications (PIM) use in a 30 
population of community-based multi-compartment compliance aid (MCA) users in North-31 
East Scotland. 32 
Methods: Data for MCAs dispensed by 48 of the 50 community pharmacies in Aberdeen City 33 
between 1st June to 31st October 2014, together with concurrently prescribed medications, 34 
patient demographics and Carstairs Index of social deprivation were recorded. Drug-specific 35 
quality indicators for PIMs from the Swedish National Board of Health and Welfare were 36 
applied and bivariate logistic regression analysis used to assess for associations with 37 
demographic variables. 38 
Results: The median age was 82 years (range 12-105 years old, 59% female).  A total of 1977 39 
PIMs were identified affecting 57.8% of patients. A quarter of patients were prescribed ≥ 10 40 
medications and 43% had a prescription containing at least one clinically significant drug-drug 41 
interaction (DDI). Ten drug groups accounted for 76% of all DDIs. A significant increase in 42 
the risk for at least one PIM was associated with female gender (for all indicators of PIM use), 43 
age less than 80 years (three or more psychotropic medicines (OR 5.88, 2.96-11.70, p< 0.001) 44 
and lower socioeconomic status (prescription of ≥ 10 medications (OR: 1.43, 95% CI: 1.16-45 
1.78), prescription of a long-acting benzodiazepine (OR: 1.84, CI: 1.14-2.98).  46 
Conclusions: MCA use is associated with a significant incidence of PIMs particularly affecting 47 
those under the age of 80 years and those living in deprived areas. Our findings indicate the 48 
need for a more aggressive multidisciplinary approach to the review of the medications 49 




What is known about this subject 52 
 Multi-compartment compliance aid devices are used increasingly in the UK and 53 
Western Europe with the intention to maximise patient medication adherence, optimise 54 
treatment benefits and minimise economic waste. 55 
What this study adds 56 
 Multi-compartment compliance aid use is associated with a significant number of PIMs 57 
including drug-drug interactions. 58 
 These mainly affect those under 80 years of age and those living in the most socially 59 
deprived areas. 60 
 To minimise PIM prescribing and the potential for patient harm there is a need for a 61 
more aggressive multidisciplinary approach to the review of the medications prescribed 62 





Multi-compartment compliance aids (MCA) are compartmentalised devices, with each discrete 66 
section denoting a single dosing occasion. Formation of an MCA therefore requires 67 
repackaging of solid dosage form medications, such as tablets and capsules, from the 68 
manufacturer’s original packaging into an MCA . The primary aim of using an MCA is to 69 
maximise patient medication adherence and optimise treatment benefits. [1, 2]. However, there 70 
is a lack of robust data to support the assumption that introduction of MCAs improves 71 
medication adherence, as measured by pill counts and patient self-reporting [3]. Indeed, while 72 
patient understanding of their own medications is widely viewed as a positive influence on 73 
medication adherence [4, 5], MCA use in older people has been associated with reduced 74 
knowledge of their medications, an effect that appears to be independent of patient cognitive 75 
function [6].  76 
Despite a lack of robust evidence, MCAs are widely employed throughout Western Europe and 77 
use appears to be rapidly increasing [7-9]. Currently, there are limited data available describing 78 
the prevalence of MCA use in the United Kingdom (UK).  79 
While the use of MCAs is conceptually appealing to prescribers, concerns exist regarding the 80 
safety of medication dispensing and the appropriateness of drug prescribing using this approach 81 
[10].  The requirement to remove medications from their original packaging and insert them 82 
into an MCA increases the opportunity for error within the dispensing pharmacy. Following an 83 
audit of MCA dispensing in Australia, Carruthers et al reported that the medication incident 84 
rate was 4.3% of issued packs with the most common causes being missing medications, supply 85 
of a ceased medication, wrong strength dispensed or incorrect dosage instructions [11].   86 
There is also evidence that use of MCAs is adversely associated with quality of drug 87 
prescribing. Population-based studies comparing patients using an MCA with those receiving 88 
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routinely dispensed medications have reported that MCA use is associated with an increase in 89 
PIM prescribing and potentially clinically significant drug-drug interactions (DDIs) [12, 13]. 90 
Belfrage et al reported recently on the results of a small study in a 100 patients using the 91 
Screening Tool of Older Persons’ Potentially inappropriate Prescriptions (STOPP) to assess 92 
medicines issued to older patients admitted to hospital [14]. The authors reported a significantly 93 
greater proportion of PIMs in patients using an MCA [14]. Similarly, in a longitudinal study of 94 
older patients pre and post commencement of an MCA, Wallerstedt et al reported a sustained 95 
increase in PIMs following the introduction of an MCA, which the authors postulated may be 96 
related to reduced frequency of medication review once under the MCA system [15]. The 97 
paucity of data supporting the use of MCAs as an aid to optimise medication adherence together 98 
with data indicating increased medication incidents and poorer quality prescribing, has led to 99 
growing concern over what may be seen as an increasingly untargeted approach to the use of 100 
MCAs [10].  101 
The majority of studies assessing PIM use in MCA users have been conducted in Scandinavia 102 
and continental Europe [12, 13, 14, 15]. The aim of this study was to investigate the extent of 103 
PIMs in a population of community-based MCA users in Scotland. 104 
Methods 105 
All community pharmacies (n=50) in Aberdeen City, Grampian, Scotland were sent a study 106 
protocol and invitation to participate in the study by post and email with a follow-up phone call 107 
from the research pharmacist one week later.  Forty-eight pharmacies (96%) gave consent to 108 
participate. For each MCA dispensed during the study period (1st June to 31st October 2014) 109 
the following information was recorded electronically: patient demographics, medications 110 
dispensed (name, strength, formulation) into an MCA, number of prescribed medications 111 
dispensed out with the MCA, frequency of MCA dispensing, MCA distribution method and 112 
pharmacy postal code as a surrogate for patient socioeconomic status. This information was 113 
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collected from patient pharmacy records, prepared MCA packs and prescriptions. Patient 114 
socioeconomic status was determined using the Carstairs index score, a measure of social 115 
deprivation designed originally for use in Scotland and includes factors such as employment 116 
status, housing and overcrowding [16]. Patient socioeconomic status was expressed as a decile 117 
of the Carstairs index score with decile 1 being the most deprived and decile 10 the least 118 
deprived. 119 
Because clinical data were absent and to permit international comparison, PIMs were assessed 120 
using the National Indicators for Quality of Drug Therapy in Older Persons issued by the 121 
Swedish National Board of Health and Welfare [13, 15, 17] as listed in Table 1. Potential DDIs 122 
for medications dispensed via the MCA were assessed using the drug interaction software 123 
package Lexi-Interact™ Lexicomp® [18], which classifies DDIs into 5 classes (A- no 124 
interaction, B- no action needed, C- monitor therapy, D- modify regimen and X- avoid 125 
combination). Only drug combinations classified as class-D or class-X interactions, both 126 
denoting potential for clinically significant interaction, were recorded. PIMs and DDIs were 127 
assessed by two independent researchers (Specialist Registrar in Clinical Pharmacology DC 128 
and Research Pharmacist DS) and disagreements were reviewed by a third researcher 129 
(Consultant Clinical Pharmacologist JSM).  130 
Statistical Analysis 131 
Binary Logistic regression analysis was used in the multivariate analysis of associations 132 
between indicators of PIM and demographic variables of gender, age and Carstairs index of 133 
social deprivation (expressed as odds ratio with 95% confidence intervals).  134 
Ethics Statement  135 
This study was registered as an audit with the Quality Governance and Risk Unit, NHS 136 
Grampian (ID: 3044), and was therefore exempted from NHS Ethical review. Patient data was 137 
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anonymised at the time of data collection and stored electronically on a password-protected 138 
file. 139 
Results 140 
During the study period, MCAs were issued to 2060 patients (59% female, median age 82 years 141 
(IQR: 70-87), range 12 to 105 years). The majority (60.3%) of MCAs users were in the top 142 
50% for socioeconomic status (Carstairs deciles 6 to 10).  143 
Patients were prescribed a mean of 7.4 distinct medications per prescription (SD: 3.4, range 1-144 
23), of which, a mean of 6.4 were dispensed into an MCA (SD: 2.8., Range 1-21). Only one 145 
medication was dispensed in an MCA for 2.3% (47) of the study group, while 25.1% (518) 146 
were prescribed 10 or more distinct medications. Almost half of the study group (47.9%, 988) 147 
had at least one medication concurrently dispensed outside of the MCA, of which 8.1% (80) 148 
were prescribed five or more medications outside of the MCA. Over a fifth of the study cohort 149 
(21.3%, 438) had at least a quarter of their total medications dispensed outside their MCA, and 150 
4% (82) had more medications dispensed outside their MCA than within. The majority (72.1%, 151 
1486) of patients had their MCA issued on a weekly basis with 0.5% (10) issued fortnightly 152 
and 27.3% (563) issued monthly. Only 13.9% (n=286) of the study population collected their 153 
medications in person.  154 
A total of 1977 PIMs were identified in the study group, with at least one PIM occurring in 155 
57.8% (1190) of the cohort, two or more in  25.1% (518) and three or more in  7.5% (n=154). 156 
The maximum number of individual PIM criteria for any one patient was 5 (10 patients) and 157 
the maximum total number of PIMs for a single patient was 21 caused by 12 medications (1 158 
patient). The most frequent PIMs were potentially clinically significant DDIs (43.1%), 10 or 159 
more distinct medications (25.1%) and medications with anticholinergic activity (16.6%). The 160 




The adjusted odds ratios for PIMs and prescribing quality indicators are reported in Table 3. 163 
After adjustment for age and Carstairs index score of social deprivation, PIMs were more 164 
frequently observed in females (OR 1.25, 1.04-1.51, p<0.05) for all indicators of PIM, except 165 
polypharmacy (10 or more medicines). PIMs of any type were more frequently observed in 166 
patients under 65 years of age compared with those over 80 years (OR 1.68, 1.27-2.20, 167 
p<0.001).  Specifically those under 65 years of age were 15 times more likely to be prescribed 168 
three or more psychotropic medications (OR 15.17, 7.80-29.46, p<0.001) and four times more 169 
likely to be prescribed a long acting benzodiazepine (OR 4.35, 2.49-7.60, p<0.001) or an 170 
anticholinergic drugs (OR 3.77, 2.79-5.10,p<0.001). A similar pattern was observed for those 171 
aged 65-79 years with PIMs of any type being twice as likely to occur than in those over 80 172 
years of age (OR 2.0, 1.6-2.53, p<0.001). Specifically those 65 to 79 years of age were 173 
significantly more likely to be prescribed three or more psychotropic medications (OR 5.88, 174 
2.96-11.70, p< 0.001).  175 
PIMs were significantly associated with low socioeconomic status, with those in Carstairs 176 
deciles 1-5 having a 30% increased risk of a PIM of any type (OR: 1.3, CI: 1.06-1.58). 177 
Specifically, polypharmacy (≥ 10 medicines) (OR: 1.43, 95% CI: 1.16-1.78), and prescription 178 
for a long-acting benzodiazepine (OR: 1.84, CI: 1.14-2.98).  179 
A total of 1359 potentially clinically significant DDIs were identified with 43.1% (887) MCA 180 
users having at least one DDI. Medications from 33 different drug groups were involved in 181 
potentially clinically significant DDIs. The maximum number of potentially clinically 182 
significant DDIs recorded for a single patient was 19 caused by 12 medications. DDIs were 183 
more likely to occur in those with polypharmacy (>10 prescription medications in MCA) (3.95, 184 
3.18-4.92, p<0.001), females (1.29, 1.07-1.55, p<0.01) and those aged 65 to 79 years olds (1.62, 185 
1.31-2.02, p<0.001). The ten top drug groups accounting for 72.7% of DDIs were 186 
antidepressants (13.9%), calcium supplements (9.2%), statins (8.5%), antiplatelets (7.9%), 187 
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proton pump inhibitors (6.9%), anticonvulsants (6.1%), antihypertensive agents (6.0%). 188 
antipsychotics (5.6%), levothyroxine (5.0%) and neuropathic analgesics (3.6%).  189 
Discussion 190 
This is the first study in the UK to report the prevalence of PIMs in a population of MCA users 191 
in the community. Over half of the patients issued with an MCA had at least one PIM and more 192 
than two fifths at least one potential clinically significant DDI. While previous studies have 193 
reported similar levels of PIM, the rate for potentially clinically significant DDIs observed in 194 
our study are five-fold greater than the 8-9% reported for an older Swedish population [12, 13]. 195 
The reasons for the apparent increase in prevalence of DDis is unclear but may be due to the 196 
wider use of medications such as psychotropic medications that are particularly associated with 197 
DDis in the relatively younger population seen in this study [12, 13].  198 
The adjusted odds ratio for all the indicators for PIMs were increased in those under the age of 199 
65 years compared to those aged ≥ 80 years, particularly for use of ≥ three psychotropic 200 
medications and long-acting benzodiazepines, possibly reflecting the nature of the disease 201 
burden (mental health issues) in the under 65 year age group necessitating MCA use. Of interest 202 
is the observed increase in the adjusted odds ratio for all but one of the indicators for PIMs in 203 
those aged 65-79 years relative to those ≥ 80 years. This observation that has been previously 204 
reported by others and is believed to be due to the healthy survivor effect in those ≥ 80 years 205 
of age [12, 19]. Nonetheless, these findings indicate the need to focus particular attention on 206 
prescribing in MCA users under the age of 80 years.    207 
To the best of the author’s knowledge socioeconomic status has not been included in previous 208 
studies reporting medication safety in MCA users. A significant relationship was observed 209 
between social deprivation and PIM occurrence in the lowest socioeconomic groups, in 210 
particular polypharmacy or a prescription for a long-acting benzodiazepine. It is well 211 
recognised that individuals of lower socioeconomic status tend to experience worse health and 212 
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higher levels of anxiety and it is possible that these observations reflect an increased disease 213 
burden [20, 21]. 214 
Unavoidably, a proportion of MCA users (almost half of our study population) require 215 
medications such as inhalers, which are not compatible with dispensing into an MCA. 216 
However, our finding that over a fifth of the study population had more than a quarter and 217 
almost one in twenty had more than half of their medications dispensed outwith an MCA 218 
detracts from the simplicity of application and the goal of improved adherence, which MCAs 219 
are intended to achieve [15].  220 
There is an increased prevalence of both cognitive impairment and renal dysfunction amongst 221 
MCA users, indicating a higher burden of disease in this patient population [14]. It is therefore 222 
unsurprising that only 14% of the patients in this study collected their prescriptions in person. 223 
However, missing this opportunity for direct pharmacist-patient interaction may be significant 224 
since regular interaction between pharmacists and patients has been associated with improved 225 
medication adherence [22]. Our finding that more than two fifths of subjects were exposed to 226 
a potential DDI further reinforces the importance for the pharmacist and prescribing physician 227 
to collaboratively assess both the MCA user and their prescription on a regular basis. 228 
There is little data regarding the prevalence of MCA use in the UK, however in 2001, Nunney 229 
et al estimated that there were 100,000 MCA users in the UK, equating to a 170/100,000 of the 230 
population [23]. Our data suggest that the prevalence of MCA use in 2015 is now 900/100,000 231 
of the population, representing a greater than five-fold increase over a 14 year period, which 232 
appears disproportionate to the 1.2 fold increase in the UK older population over the same 233 
period [24, 25].  234 
Study Strengths and Weaknesses  235 
Although this study provides insight into medication use by MCA users under 65 years of age, 236 
the criteria used were originally validated in an older population (>65 years) and therefore may 237 
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not be fully generalisable to all age groups [17]. However, it may be argued that the PIM criteria 238 
are equally applicable to all age groups and the presence of morbidity and comorbidity may be 239 
more relevant than age per se.    240 
Our finding that socioeconomic status appears to be independently associated with PIMs is 241 
significant, however we did not directly account for patient disease burden which is also 242 
directly associated with socioeconomic status [20]. Therefore, the observed relationship 243 
between socioeconomic status and PIM may be largely accounted for by disease burden. 244 
Patient socioeconomic status was determined from the supplying pharmacy postcode, thus 245 
assuming that both patient and pharmacy lay within the same geographical area. It has been 246 
reported that almost 90% of patients live within 1.6 kilometres of their pharmacy suggesting 247 
that this is a reasonable assumption to make [26]. The study population were exclusively 248 
residents of the North East of Scotland and hence its findings may not be generalisable to the 249 
whole UK population and beyond. 250 
The lack of clinical data prevented the use of more comprehensive screening tools for 251 
inappropriate medicine use such as the STOPP and START criteria, which prevented 252 
assessment of potential prescribing omissions and clinically relevant inappropriate medicine 253 
use. Therefore, our results are likely to be an underestimation of the actual PIM prevalence. 254 
Conclusions 255 
A significant proportion of MCA users in this study were prescribed PIMs including DDIs, 256 
with those under the age of 80 years and those living in the poorest areas at greater risk. The 257 
simplification of medication consumption, which the MCA is designed to provide, appears to 258 
be confounded in a significant number of individuals by the concurrent supply of medications 259 
outwith the MCA system. Our findings indicate a need for a more aggressive multidisciplinary 260 
approach (involving prescriber, dispensing pharmacist and patient) to the review of the 261 
12 
 
medications prescribed to MCA users, which is particularly poignant given the apparent 262 
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Legend for Tables  358 
Table 1: Indicators of Potentially Inappropriate Medicines with Qualifying Drug Classes. 359 
Presence of a PIM was dependent solely on the prescription of a qualifying medication 360 
regardless of preparation, dose or indication. (ATC Denotes Anatomical Therapeutic Chemical 361 
WHO Classification System). 362 
 363 
Table 2: Prevalence of Potentially Inappropriate Medicines Associated with MCA (n=2060) 364 
 365 
Table 3: Adjusted Odds Ratios For Potentially Inappropriate Medicine Use According To 366 
Prescribing Quality Indicators, Adjusted for Age, Gender, Residence And Carstairs Index 367 
Score.  368 
(NS denotes variable-indicator combinations that were not significant in the multivariate analysis model. * 369 
denotes p<0.05 relative to reference group within variable category. ** denotes p<0.01 and *** denotes 370 
p<0.001. LA Benzo = long-acting benzodiazepine. Any PIM = presence of at least one indicator for potentially 371 
inappropriate medicine, ref = reference variable.) 372 
